68913-85-9

Usage

Uses

Used in Organic Synthesis:
2,3,4-TRIMETHOXYPHENYLACETONITRILE is used as an intermediate in organic synthesis for its versatile reactivity and functional groups, contributing to the production of various pharmaceuticals, agrochemicals, and other fine chemicals.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2,3,4-TRIMETHOXYPHENYLACETONITRILE is utilized as a key component in the development of pharmaceuticals, owing to its potential to form biologically active molecules that can address specific medical needs.
Used in Materials Science:
2,3,4-TRIMETHOXYPHENYLACETONITRILE may also find applications in materials science, where its unique structure and properties could be leveraged to create novel materials with specific characteristics for various industrial applications.

InChI:InChI=1/C11H13NO3/c1-13-9-5-4-8(6-7-12)10(14-2)11(9)15-3/h4-5H,6H2,1-3H3

Upstream product

• 68913-84-8 2-[(Z)-Hydroxyimino]-3-(2,3,4-trimethoxy-phenyl)-propionic acid 
• 1133-49-9 2,3,4-trimethoxybenzyl chloride 
• 2103-57-3 2,3,4-trimethoxybenzaldehyde 
• 71989-96-3 2,3,4-trimethoxybenzylalcohol 
• 773837-37-9 sodium cyanide 
• 80054-01-9 2,3,4-trimethoxybenzyl bromide 

Downstream Products

• 89155-11-3 2-Amino-3-(2,3,4-trimethoxy-phenyl)-benzo[4,5]thieno[3,2-b]pyran-4-one 
• 83485-59-0 2-Amino-3-(2,3,4-trimethoxy-phenyl)-thiochromen-4-one 
• 22480-91-7 (2,3,4-trimethoxy-phenyl)-acetic acid 
• 106318-35-8 2-Isopropyl-5-[3-(2-methoxy-phenoxy)-propylamino]-2-(2,3,4-trimethoxy-phenyl)-pentanenitrile 
• 103525-48-0 2-Isopropyl-5-{[3-(2-methoxy-phenoxy)-propyl]-methyl-amino}-2-(2,3,4-trimethoxy-phenyl)-pentanenitrile 
• 116753-61-8 3-Methyl-2-(2,3,4-trimethoxy-phenyl)-butyronitrile 

Relevant academic research and scientific papers

TUBULIN BINDING AGENTS

The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene. The second substituent on the B ring may for example be a substituent which has been found to provide enhanced tubulin binding activity (for example a carbonyl group), or may be a substituent that facilitates functionalisation of the B ring (for example an hydroxyl or amine group), or it may be a binding agent for a target that is preferentially expressed on vasculature undergoing angiogenesis, and not expressed on quiescent vasculature.

Process of preparing discotic liquid crystalline compounds

The invention relates to a process of preparing a discotic liquid crystalline compound by intramolecular oxidative cyclisation of a diaryl compound in an organic solvent in the presence of a strong acid, characterized in that an oxidative agent comprising a chrom(VI)oxide derivative is used, to discotic liquid crystalline compounds obtainable from said process, to liquid crystalline media, (co)polymers or polymer networks with columnar phases comprising said discotic liquid crystalline compounds, and to the use of said discotic liquid crystalline compounds, liquid crystalline media or liquid crystalline (co)polymers with columnar phases for liquid crystal displays, optical elements like polarizers, compensators or colour filters, chemical sensors, charge transport materials, optical storage media, nonlinear optics, decorative pigments, adhesive or synthetic resins with anisotropic mechanical properties.

Anellated dihydropyridines and the use thereof for the production of pharmaceutical preparation

Compound of general formula I STR1 wherein A is a benzo or thieno group; R1 is (C4-6)cycloalkyl, (C4-6)cycloalkyl-(C1-5)alkyl or STR2 R2, m, R3, R4, R and u are defined as in the specification, and pharmaceutical preparations containing this compound and the new pharmaceutical uses thereof.

Degradation of 3-aryl-2-hydroxyiminopropionic acids into arylacetonitriles using 1,1'-carbonyldiimidazole or 2,2'-oxalyldi(o-sulfobenzimide)

1,1'-Carbonyldiimidazole (1) is a useful reagent for the preparation of arylacetonitriles (9) from 3-aryl-2-hydroxyiminopropionic acids (8), and 2,2'-oxalyldi (o-sulfobenzimide) (2) can also be used for this purpose under essentially neutral conditions.